Schizophrenia Clinical Trials in Houston
View 17 new treatments for Schizophrenia in Houston, TX, and nearby areas, such as League City, Pearland and Sugar Land. Every day, Power helps hundreds of schiz patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
RL-007 for Cognitive Impairment in Schizophrenia
Recognify Life Sciences Clinic, Houston + 2 more
This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More
Verified
Recruiting
Phase 2
Est. 6 - 12 Weeks
Gary Walker, PhD
Study Director
TMS for Smoking Cessation in Schizophrenia
Research Clinic, Houston + 2 more
This trial uses a magnetic pulse device to help people with schizophrenia stop smoking. It targets specific brain areas involved in both conditions. The goal is to see if this method is effective for this particular group. This method has been shown to decrease cigarette consumption in schizophrenia patients.Show More
Verified
Recruiting
No Placebo Trial
N/A
Est. 4 - 6 Weeks
Xiaoming Du, PhD
Principal Investigator
Cariprazine for Adolescent Schizophrenia
Allergan Clinic, The Woodlands + 1 more
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Recruiting
Phase 3
Est. 5 - 8 Weeks
Paul Yeung
Study Director
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Houston + 2 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
KarXT for Schizophrenia
Karuna Clinic, Richmond + 3 more
This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Bristol-Myers Squibb
Study Director
Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Houston + 1 more
This trial tests if a medicine called Iclepertin can help improve memory and learning in adults with schizophrenia. Participants take Iclepertin daily while continuing their usual medication. Doctors regularly check their mental abilities and health throughout the study. Iclepertin is being studied for its potential to improve cognitive functions in schizophrenia.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Houston + 1 more
This trial is testing a new medicine called iclepertin to see if it can help adults with schizophrenia improve their learning and memory. Participants will take either the medicine or a non-active substance while continuing their regular medication. Doctors will regularly check their mental abilities and overall health over several months.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Valbenazine for Schizophrenia
Neurocrine Clinic, Houston + 1 more
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Clinical Development Lead
Study Director
Cariprazine for Pediatric Schizophrenia
AbbVie Clinic, Houston + 4 more
This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director
Ocrelizumab for Psychosis
Research Clinic, Houston + 1 more
Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and also feeling that other people do not like them. If this disease is caused by auto-antibodies, typically the person is well until they are 15 years of age or older, but seldom older than 35 years. Then, in a matter of a few months they begin to have hallucinations and the other symptoms. Doctors still do not know whether some people with schizophrenia or bipolar disease have auto-antibodies attacking their brain. For this reason, in this study some of these patients will receive a treatment that suppresses the auto-antibodies and their symptoms after treatment will be compared with the symptoms of a group of similar patients who are given a preparation that looks like the real treatment, but it is not.Show More
Recruiting
Phase 1 & 2
Est. 6 - 12 Weeks
Joseph C Masdeu, MD, PhD
Principal Investigator
Page 1 of 2
Frequently Asked Questions
Explore related conditions